A Multi-centre, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate(TDF) Treatment in Chinese Chronic Hepatitis B (CHB) Subjects Following Failure of Multiple Nucleos(t)Ide Analogues(NAs)
Phase of Trial: Phase IV
Latest Information Update: 05 Nov 2019
Price : $35 *
At a glance
- Drugs Tenofovir disoproxil fumarate (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 17 Sep 2018 Status changed from active, no longer recruiting to completed.
- 23 Aug 2018 Planned End Date changed from 4 Aug 2018 to 14 Aug 2018.
- 13 Oct 2017 Planned End Date changed from 1 Aug 2018 to 4 Aug 2018.